Biocardia Inc Cash Flow Conversion Efficiency
Biocardia Inc cash flow conversion efficiency. Based on the latest financial reports, Biocardia Inc (BCDA) has a cash flow conversion efficiency ratio of -0.643x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($2.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biocardia Inc (1995–2025)
Cash flow conversion efficiency of Biocardia Inc from 1995 to 2025. This chart illustrates how Biocardia Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biocardia Inc (BCDA) share price today for real-time trading data and today's change.
Biocardia Inc Cash Flow Conversion Ratio Explained
Biocardia Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biocardia Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocardia Inc ranked by their cash flow conversion efficiency. Also see Biocardia Inc (BCDA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vision Sigma
TA:VISN
|
-0.017x |
|
System1 Inc
NYSE:SST
|
-0.611x |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.148x |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
N/A |
|
City Steel Public Company Limited
BK:CITY
|
0.004x |
|
Triton Holding Public Company Limited
BK:TRITN
|
-0.010x |
|
Swoop Holdings Ltd
AU:SWP
|
-0.066x |
|
Huge Group Ltd
JSE:HUG
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Biocardia Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Biocardia Inc from 1995 to 2025. Review cash generation quality of Biocardia Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $895.00K | $-7.44 Million | -8.308x | +13.36% |
| 2024-12-31 | $837.00K | $-8.03 Million | -9.589x | -254.11% |
| 2023-12-31 | $-1.60 Million | $-9.97 Million | 6.222x | +388.22% |
| 2022-12-31 | $4.89 Million | $-10.56 Million | -2.159x | -116.07% |
| 2021-12-31 | $10.38 Million | $-10.37 Million | -0.999x | -55.05% |
| 2020-12-31 | $19.18 Million | $-12.36 Million | -0.644x | +83.83% |
| 2019-12-31 | $2.37 Million | $-9.45 Million | -3.985x | -36.53% |
| 2018-12-31 | $3.79 Million | $-11.07 Million | -2.919x | -274.52% |
| 2017-12-31 | $11.12 Million | $-8.67 Million | -0.779x | -190.51% |
| 2016-12-31 | $20.58 Million | $-5.52 Million | -0.268x | -1223.91% |
| 2015-12-31 | $13.87 Million | $331.00K | 0.024x | +51.08% |
| 2014-12-31 | $13.54 Million | $214.00K | 0.016x | +678.90% |
| 2013-12-31 | $13.31 Million | $27.00K | 0.002x | +108.70% |
| 2012-12-31 | $13.29 Million | $-310.00K | -0.023x | +90.19% |
| 2011-12-31 | $12.98 Million | $-3.09 Million | -0.238x | +81.76% |
| 2010-12-31 | $3.28 Million | $-4.28 Million | -1.304x | -301.89% |
| 2009-12-31 | $14.74 Million | $-4.78 Million | -0.325x | -28.78% |
| 2008-12-31 | $10.70 Million | $-2.70 Million | -0.252x | +67.22% |
| 2007-12-31 | $61.28K | $-47.12K | -0.769x | +85.32% |
| 2006-12-31 | $141.55K | $-741.46K | -5.238x | -103.10% |
| 2005-12-31 | $176.73K | $-455.82K | -2.579x | -231.63% |
| 2004-12-31 | $963.58K | $-749.42K | -0.778x | -338.65% |
| 2003-12-31 | $1.68 Million | $-297.66K | -0.177x | +24.45% |
| 2002-12-31 | $2.09 Million | $-491.22K | -0.235x | +47.81% |
| 2001-12-31 | $3.40 Million | $-1.53 Million | -0.450x | -103.53% |
| 2000-12-31 | $6.27 Million | $-1.38 Million | -0.221x | +51.39% |
| 1999-12-31 | $2.20 Million | $-1.00 Million | -0.455x | -120.78% |
| 1998-12-31 | $3.40 Million | $-700.00K | -0.206x | -68.82% |
| 1997-12-31 | $4.10 Million | $-500.00K | -0.122x | 0.00% |
| 1996-12-31 | $4.10 Million | $-500.00K | -0.122x | +96.68% |
| 1995-12-31 | $-71.75K | $263.39K | -3.671x | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more